ORIGINAL ARTICLE
Investigation of ZIP4, ZO-1, and CLAUDIN-1 expression in thyroid tumours by immunohistochemistry and real-time polymerase chain reaction methods
1
Department of Pathology, University of Health Sciences Gazi Yaşargil Trainning and Research Hospital, Diyarbakır, Turkey
2
Department of Pathology, Dicle University, Medical School, Diyarbakır, Turkey
Submission date: 2023-02-22
Acceptance date: 2023-09-20
Publication date: 2024-02-01
Corresponding author
Ulaş Alabalık
Ulaş Alabalık Department of Pathology Dicle University Faculty of Medicine 21280, Sur/Diyarbakır, Turkey
Ulaş Alabalık Department of Pathology Dicle University Faculty of Medicine 21280, Sur/Diyarbakır, Turkey
Pol J Pathol 2023;74(4):248-255
KEYWORDS
TOPICS
ABSTRACT
Thyroid neoplasms are the most common endocrine malignancies. ZIP4 is an intramembranous zinc trans membrane protein. Zinc plays a central role in the activation of transcription factors, and zinc transporters. This affects tumour migration, invasion, and cell proliferation. ZO-1 and Claudin-1 are important tight junction proteins whose amounts increase and decrease in various cancers.
In this study, we aimed to investigate the expression of ZIP4, ZO-1, and Claudin-1 in thyroid tumours and the relationship of this expression with tumour types and prognostic parameters.
ZIP4, ZO-1, and Claudin-1 were studied in all cases by immunohistochemical and Real-Time PCR methods.
ZIP4 and Claudin-1 tended to be expressed more in cases with tumours, while ZO-1 in cases with and without tumours. Expression of ZIP4 and Claudin-1 by real-time polymerase chain reaction showed a significant difference between histological subtypes, and this difference was not observed with ZO-1. It was observed that the presence of metastasis increased with the expression of ZIP4 and Claudin-1, and there was no significant change with ZO-1.
We think that Claudin-1 and ZIP4 expression can be used as an important marker in terms of showing poor prognosis and susceptibility to metastasis in thyroid tumours, and in developing targeted therapy.
In this study, we aimed to investigate the expression of ZIP4, ZO-1, and Claudin-1 in thyroid tumours and the relationship of this expression with tumour types and prognostic parameters.
ZIP4, ZO-1, and Claudin-1 were studied in all cases by immunohistochemical and Real-Time PCR methods.
ZIP4 and Claudin-1 tended to be expressed more in cases with tumours, while ZO-1 in cases with and without tumours. Expression of ZIP4 and Claudin-1 by real-time polymerase chain reaction showed a significant difference between histological subtypes, and this difference was not observed with ZO-1. It was observed that the presence of metastasis increased with the expression of ZIP4 and Claudin-1, and there was no significant change with ZO-1.
We think that Claudin-1 and ZIP4 expression can be used as an important marker in terms of showing poor prognosis and susceptibility to metastasis in thyroid tumours, and in developing targeted therapy.
REFERENCES (35)
1.
Morris LG, Sikora AG, Tosteson TD, and Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid 2013; 23: 885-891.
2.
Ertaş B, Kaya H, Özdilek A, et al. Metastatic neck disease in multifocal thyroid papillary cancer. Med Bull Haseki 2018. 56: 313-318.
3.
Rahman GA, Extent of surgery for differentiated thyroid cancer: recommended guideline. Oman Med J 2011; 26: 56-8.
4.
Huang C, Cui X, Sun X, Yang J, and Li M. Zinc transporters are differentially expressed in human non-small cell lung cancer. Oncotarget 2016; 7: 66935-66943.
5.
Kimura T, Kambe T. The functions of metallothionein and ZIP and ZnT transporters: an overview and perspective. Int J Mol Sci 2016; 17: 336.
6.
Kang X, Chen R, Zhang J, et al. Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status. Asian Pac J Cancer Prev 2015; 16: 3355-3360.
7.
Chen QG, Zhang Z, Yang Q, et al. The role of zinc transporter ZIP4 in prostate carcinoma. Urol Oncol 2012; 30: 906-911.
8.
Ichikawa-Tomikawa N, Sugimoto K, Satohisa S, Nishiura K, Chiba H. Possible involvement of tight junctions, extracellular matrix and nuclear receptors in epithelial differentiation. J Biomed Biotechnol 2011; 2011: 253048.
9.
Zihni, C, Mills C, Matter K, and Balda MS. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol 2016; 17: 564-580.
10.
Babkair H, Yamazaki M, Uddin MS, et al. Aberrant expression of the tight junction molecules claudin-1 and zonula occludens-1 mediates cell growth and invasion in oral squamous cell carcinoma. Hum Pathol 2016; 57: 51-60.
11.
Zwanziger D, Badziong J, Ting S, et al. The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness. Endocr Relat Cancer 2015; 22: 819-830.
12.
Alabalık U, Türkcü G, Keleş AN, et al. Can aquaporins be used as diagnostic and prognostic markers for uterine smooth muscle tumours? Biotechnol Biotechnolog Equipment 2017; 31: 148-155.
13.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
14.
Ruiz EML, Niu T, Zerfaoui M, et al. A novel gene panel for prediction of lymph-node metastasis and recurrence in patients with thyroid cancer. Surgery 2020; 167: 73-79.
15.
Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: A prospective study on 715 patients. J Clin Endocrinol Metab 2011; 96: 1352-1359.
16.
Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAFV600E mutational status of 977 cases. Ann Surg Oncol 2013; 20: 2266-2273.
17.
Cabanillas ME, McFadden DG, and Durante C. Thyroid cancer. Lancet 2016; 388: 2783-2795.
18.
Fan Q, Cai Q, Li P, et al. The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget 2017; 8: 90090-90107.
19.
Ishida S, Kasamatsu A, Endo-Sakamoto Y, et al. Novel mechanism of aberrant ZIP4 expression with zinc supplementation in oral tumorigenesis. Biochem Biophys Res Commun 2017; 483: 339-345.
20.
Feustel A, Wennrich R, Steiniger D, Klauss P. Zinc and cadmium concentration in prostatic carcinoma of different histological grading in comparison to normal prostate tissue and adenofibromyomatosis (BPH). Urol Res 1982; 10: 301-303.
21.
Ogunlewe JO, Osegbe DN. Zinc and cadmium concentrations in indigenous blacks with normal, hypertrophic, and malignant prostate. Cancer 1989; 63: 1388-1392.
22.
Fluge Ø, Haugen DRF, Lillehaug JR, and Varhaug JE. Difference in patterns of met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue. World J Surg 2001; 25: 623-631.
23.
Rebuffat SA, Kammoun-Krichen M, Charfeddine I, et al. IL-1β and TSH disturb thyroid epithelium integrity in autoimmune thyroid diseases. Immunobiology 2013; 218: 285-291.
24.
Bai N, Hou D, Mao C, et al. MiR-376c-3p targets heparin-binding EGF-like growth factor (HBEGF) to inhibit proliferation and invasion in medullary thyroid carcinoma cells. Arch Med Sci 2020; 16: 878-887.
25.
Du J, Zhang F, Zhang L, Jia Y, Chen H. MicroRNA-103 regulates the progression in endometrial carcinoma through ZO-1. Int J Immunopathol Pharmacol 2019; 33: 2058738419872621.
26.
Liu H, Wen T, Zhou Y, et al. DCLK1 plays a metastatic- promoting role in human breast cancer cells. Biomed Res Int 2019;15: 1061979.
27.
Süren D, Yildirim M, Sayiner A, et al. Expression of claudin 1, 4 and 7 in thyroid neoplasms. Oncol Lett 2017; 13: 3722-3726.
28.
Abd El Atti RM and Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 2012; 24: 175-184.
29.
Hoellen F, Waldmann A, Banz-Jansen C, et al. Claudin-1 expression in cervical cancer. Mol Clin Oncol 2017; 7: 880-884.
30.
Szabó I, Kiss A, Schaff Z, Sobel G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol 2009; 24: 1607-1615.
31.
Benczik M, Galamb A, Koiss R, et al. Claudin-1 as a Biomarker of cervical cytology and histology. Pathol Oncol Res 2016; 22: 179-188.
32.
Yamamoto D, Kayamori K, Sakamoto K, et al. Intracellular claudin-1 at the invasive front of tongue squamous cell carcinoma is associated with lymph node metastasis. Cancer Sci 2020; 111: 700-712.
33.
Szasz AM, Tokes AM, Micsinai M, et al. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Experimental Metastasis 2011; 28: 55-63.
34.
Mendonsa AM, Na TY, Gumbiner BM. E-cadherin in contact inhibition and cancer. Oncogene 2018; 37: 4769-4780.
35.
Liu M, Yang J, Zhang Y, et al. ZIP4 promotes pancreatic cancer progression by repressing ZO-1 and Claudin-1 through a ZEB1-dependent transcriptional mechanism. Clin Cancer Res 2018; 24: 3186-3196.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
